China is a one of the most important regions for the booming obesity market, thanks to government incentives and changing ...

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

This study aims to investigate the association between sarcopenic obesity and dementia risk in community-dwelling older adults in China, utilizing a nationally representative dataset. Furthermore, we ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094.